April 12th 2024
LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Unexpected Hospitalizations Result in Unfavorable Outcomes in Head and Neck Cancer
August 5th 2020A study conducted by the Roswell Park Comprehensive Cancer Center found that patients undergoing radiation therapy for head and neck cancers were at a higher risk of less-favorable outcomes if they were unexpectedly hospitalized for dehydration, fever, or other ailments.
Phase 2 MAESTRO Study Fails to Meet Primary Endpoint of PFS in Head and Neck Cancer
July 5th 2020The study of temsirolimus and cetuximab versus temsirolimus alone in patients with recurrent or metastatic cetuximab-resistant head and neck cancer did not meet its primary end point of improved progression-free survival.
FDA Approves Gardasil 9 for Prevention of Oropharyngeal, Head & Neck Cancers Caused by HPV
June 15th 2020The FDA approved an expanded indication for the HPV 9-valent vaccine, recombinant for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
Staging Guidelines May be Missing Biomarkers that Affect Outcomes in OPSCC
February 17th 2020Researchers suggested that the 2017 classifications do not currently allow for uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive oropharyngeal squamous cell carcinoma.
Varying Overall Survival Indicated Depending on Institution for Patients with HNC
January 30th 2020Patients with head and neck cancer saw better overall survival when treated at academic comprehensive cancer programs and integrated network cancer programs, compared to comprehensive community cancer programs and community cancer programs.
Low-Dose Gabapentin in Combination with Methadone May Improve QOL in Patients with HNC
January 23rd 2020Administering a high dose of gabapentin also increased the percentage of patients who required no opioid during treatment, indicating that patients were possibly gleaning benefits from gabapentin in both treatment arms.
Questions Remain About the Role of Transoral Surgery for Oropharyngeal Cancer
August 19th 2019Researchers compared the swallowing-related quality-of-life scores of patients with oropharyngeal squamous cell carcinoma who received radiotherapy and patients who received transoral robotic surgery with neck dissection.
Should Surveillance Schedules Apply to HPV-Associated Oropharyngeal Squamous Cell Carcinomas?
August 16th 2019A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.